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Even after recovery from acute kidney injury, glomeruli remain vulnerable to further injury by way of interstitial ﬁbrosis. This study
is aimed at elucidating the eﬀects of post ischemia-reperfusion (I/R) treatment with trimetazidine on the progression to renal
ﬁbrosis as well as short- and intermediate-term aspects. Trimetazidine 3mg/kg or 0.9% saline was given intraperitoneally once
upon reperfusion or daily thereafter for 5 d or 8w. Renal histologic changes and related signaling proteins were assessed. After
24 h, post I/R treatment with trimetazidine signiﬁcantly reduced serum blood urea nitrogen and creatinine levels and tubular
injury accompanied with upregulation of hypoxia-inducible factor- (HIF-) 1α, vascular endothelial growth factor (VEGF), and
Bcl-2 expression. After 5 d, post I/R treatment with trimetazidine reduced renal tubular cell necrosis and apoptosis with
upregulation of HIF-1α-VEGF and tissue inhibitors of metalloproteinase activities, attenuation of matrix metalloproteinase
activities, and alteration of the ratio of Bax to Bcl-2 levels. After 8 w, however, post I/R treatment with trimetazidine did not
modify the progression of renal ﬁbrosis. In conclusion, post I/R treatment with trimetazidine allows ischemic kidneys to regain
renal function and structure more rapidly compared to nontreated kidneys, but not enough to resolute renal ﬁbrosis in
long-term aspect.
1. Introduction
Acute kidney injury (AKI) is one of the most frequent com-
plication in hospitalized patients, which is believed to be
the consequence of ischemia-reperfusion (I/R) injury [1–3].
Of importance, glomeruli remain vulnerable to additional
injury after AKI and foster progression to chronic kidney
disease (CKD) by way of interstitial ﬁbrosis, regardless of
the degree of recovery from AKI [4]. This is supported by
clinical evidence that even a transient increase in serum
creatinine has consistently been recognized as a portent of
adverse outcome [5].
As an innate response to renal I/R injury and AKI, activa-
tion of hypoxia-inducible factor- (HIF-) 1α stimulates vari-
ous cell survival signaling pathways, including a principal
pathway that attenuates oxidative stress via expression of
vascular endothelial growth factor (VEGF) [6, 7]. Signals
essential for renal protection and repair immediately after
I/R injury, however, could result in delayed renal ﬁbrosis
and CKD [8–10]. In that context, controlling excessive cell
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proliferation and extracellular matrix production would be of
key issue to establish therapeutic options that can arrest the
progression to renal ﬁbrosis.
Trimetazidine (TMZ, 1-[2,3,4-trimethoxybenzyl]pipera-
zine dihydrochloride), an anti-ischemic agent in current use,
has been shown to reduce myocardial and renal I/R injury at
both the cellular and mitochondrial levels [11, 12]. Putative
mechanisms involved reduced intracellular acidosis, pre-
served ATP stores, and inhibited inﬂammatory reactions
[13, 14]. More importantly, pretreatment with TMZ attenu-
ated the progression of renal I/R injury by mitigating apopto-
sis and interstitial ﬁbrosis in association with promoted
release of HIF-1α [15, 16]. Yet, the majority of studies have
focused on the early eﬀects of TMZ pretreated before I/R
injury [11, 14, 17]. However, the development of AKI is
diﬃcult to predict and also challenged by the inability of
timely diagnosis, which render pretreatment measures not
clinically feasible.
Thus, this study is aimed at elucidating the eﬀects of post
I/R treatment with TMZ on the progression to renal ﬁbrosis
as well as short- and intermediate-term aspects and at inves-
tigating relevant signaling pathways.
2. Materials and Methods
2.1. Animals. All experiments were approved by the commit-
tee for the Care and Use of Laboratory Animals, Yonsei
University College of Medicine, and were performed con-
forming to the Guide for the Care and Use of Laboratory Ani-
mals published by the US National Institutes of Health [18].
Male Sprague-Dawley rats (10–12w old, 250–300 g) were
anesthetized with Rompun (vial Korea, 10mg/kg, intraperi-
toneally (ip)) plus Zoletil 50 (Virbac Korea, 30mg/kg, ip).
The rats were intubated with a 16-gauge catheter and artiﬁ-
cially ventilated (Harvard Apparatus 683, Holliston, MA) at
30–35 cycles/min. The body temperature was continuously
monitored throughout the experiment and maintained
around 37°C using a heating pad.
2.2. Experimental Models and Study Groups. We employed
an established rodent model of renal I/R injury having the
Table 1: Parameters for semiquantitative assessment of histopathology.
Cell degradation Necrosis Neutrophil inﬁltration
Grade 1 No change from normal Nil Nil
Grade 2 <5% of total ﬁeld Some single-cell necrosis 1–3 cells/ﬁeld
Grade 3 5–30% of total ﬁeld Dispersed focal necrotic tubules 4–6 cells/ﬁeld
Grade 4 >30% of total ﬁeld Conﬂuent necrosis in most tubules Heavy inﬁltration
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Figure 1: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on renal function at diﬀerent time points. Renal I/R injury produced
a signiﬁcant increase in serum BUN (a) and creatinine levels (b), which were signiﬁcantly attenuated in the TMZS group at 24 h after
reperfusion. The elevated serum BUN and creatinine levels returned to their respective baseline values in all groups at 5 d after renal I/R
injury and were at similar levels at 8 w after renal I/R injury without any intergroup diﬀerences. TMZ= trimetazidine; BUN=blood urea
nitrogen. Sham= rats not underwent I/R; IRC= rats underwent ischemia (45min)-reperfusion (24 h, 5 d, and 8w); TMZS = rats treated
with TMZ (3mg/kg) upon reperfusion; TMZD= rats treated with TMZ (3mg/kg) once daily for 5 d or 8 w starting upon reperfusion.
∗P < 0 05 versus sham, #P < 0 05 versus IRC.
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longest period of ischemia to induce an appropriate degree of
renal injury while allowing long-term survival [19, 20]. After
midline incision to expose both kidneys, the left kidney was
removed in all rats except those in the sham group. The right
renal pedicle was clamped for 45min with an atraumatic
microvascular clamp and then reperfused for 24h, 5 d, or
8w to perform short-, intermediate-, and long-term assess-
ment, respectively.
The animals were randomly assigned to four groups:
(1) sham (n = 10), 0.9% saline only; (2) I/R control (IRC)
(n = 15), I/R+ 0.9% saline; (3) single TMZ posttreatment
after I/R (TMZS) (n = 15), I/R+TMZ single administration
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Figure 2: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on renal tubular apoptotic cell death. Representative histology of
renal tubules after TUNEL assay (a) and a percentage of apoptotic cells (apoptotic cells/total cells) (b). Compared to the sham groups, I/R
injury resulted in signiﬁcant apoptotic cell death in the IRC groups at 24 h and 5 d after I/R injury. TMZ signiﬁcantly attenuated apoptotic
cell death compared to the IRC groups at 24 h and 5 d after I/R injury. At 8 w after I/R injury, TUNEL assay of renal tissues demonstrated
almost full recovery of histopathologic ﬁndings in the IRC and the TMZ-treated groups, without intergroup diﬀerences.
TMZ= trimetazidine; TUNEL= terminal deoxynucleotidyl transferase-mediated uridine triphosphate nick end labeling. Sham= rats not
underwent I/R; IRC= rats underwent ischemia (45min)-reperfusion (24 h, 5 d, and 8w); TMZS = rats treated with TMZ (3mg/kg) upon
reperfusion; TMZD= rats treated with TMZ (3mg/kg) once daily for 5 d or 8w starting upon reperfusion. ∗P < 0 05 versus
sham, #P < 0 05 versus IRC.
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Figure 3: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on renal tubular cell necrosis. Representative histology of renal
tubules after and PAS staining. Compared to the sham groups, I/R injury resulted in signiﬁcant necrosis in the IRC groups at 24 h and 5 d
after I/R injury. TMZ signiﬁcantly attenuated cell necrosis compared to the IRC groups at 24 h and 5 d after I/R injury. At 8w after I/R
injury, PAS staining of renal tissues demonstrated almost full recovery of histopathologic ﬁndings in the IRC and the TMZ-treated
groups, without intergroup diﬀerences. TMZ= trimetazidine; PAS = periodic acid-Schiﬀ. Sham= rats not underwent I/R; IRC= rats
underwent ischemia (45min)-reperfusion (24 h, 5 d, and 8w); TMZS = rats treated with TMZ (3mg/kg) upon reperfusion; TMZD= rats
treated with TMZ (3mg/kg) once daily for 5 d or 8w starting upon reperfusion.
3Oxidative Medicine and Cellular Longevity
upon reperfusion; and (4) daily TMZ posttreatment after
I/R (TMZD) (n = 15), I/R+daily TMZ administration for
5 d or 8w starting upon reperfusion.
To examine the eﬀect of TMZ on renoprotection, TMZ
(3mg/kg, Sigma, St. Louis, MO) was administered to the
TMZ-treated groups while the sham and IRC groups received
equivalent amounts of 0.9% saline via ip. The dose of TMZ
was chosen based on our pilot study that investigated the
optimal dose of TMZ in terms of attenuating apoptotic cell
death after renal I/R injury (3mg/kg versus 1 and 5mg/kg,
data not shown).
2.3. Blood Urea Nitrogen (BUN) and Creatinine Analysis.
Serum samples were obtained at 24 h, 5 d, and 8w after reper-
fusion and assayed for BUN and creatinine levels using the
picric acid and diacetyl monoximemethods [21], respectively.
2.4. TUNEL Assay. Detection of apoptosis on paraﬃn
sections from each group was examined using the terminal
deoxynucleotidyl transferase-mediated uridine triphosphate
nick end labeling (TUNEL) [22]. Five visual ﬁelds from each
sample block were randomly selected and analyzed by a blind
observer using a microscope (×400). The apoptotic index was
analyzed (apoptotic cells/total cells× 100%) from a total of 20
ﬁelds per sample.
2.5. Renal Histopathology Examination. Paraﬃn-embedded
kidney tissues were cross sectioned (5-6 specimens per
group) through the midpoint to measure histologic damage.
Periodic acid-Schiﬀ (PAS) staining was performed and the
degree of tubular damage was graded on a scale from 1 to
4. Grading and deﬁnitions for cell degradation, necrosis,
and neutrophil inﬁltration are listed in Table 1 [8]. Masson’s
trichrome staining was used to assess renal interstitial ﬁbrosis
[23]. Percentages of positively stained blue areas on Masson’s
trichrome-stained sections were assessed by microscopic
review by a pathologist (Eunah Shin) to estimate the level
of ﬁbrosis. Vascular and perivascular areas were excluded
from the estimation.
2.6. Immunoblot Analysis. After processing, equal amounts
of protein from each group underwent immunoblot assay
as described previously [24]. Proteins were separated on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and immunoblotted with anti-VEGF (Santa Cruz, CA),
anti-matrix metalloproteinase- (MMP-) 2, anti-MMP-9,
anti-tissue inhibitor of metalloproteinase- (TIMP-) 1,
anti-TIMP-2 (Calbiochem, USA), anti-Bcl-2, anti-Bax,
anti-HIF-1α, and anti-actin (all from Cell Signaling
Technology, Beverly, MA). Each analysis was performed
at least three times.
2.7. Statistical Analysis. All data were expressed as mean
± standard deviation. Statistical analysis was performed using
one-way analysis of variance (ANOVA) or Student’s t-test
followed by Bonferroni correction. Values of P < 0 05 were
considered statistically signiﬁcant.
3. Results
3.1. Post I/R Treatment with TMZ Reduced Short-Term Renal
Dysfunction. Renal I/R injury produced a signiﬁcant increase
in serum BUN and creatinine levels, which were signiﬁcantly
attenuated in the TMZS group at 24h after reperfusion. The
elevated serum BUN and creatinine levels returned to their
respective baseline values in all groups at 5 d after renal I/R
injury and were at similar levels at 8w after renal I/R injury
without any intergroup diﬀerences (Figures 1(a) and 1(b)).
3.2. Post I/R Treatment with TMZ Mitigated Renal Tubular
Apoptotic Cell Death and Cell Necrosis at 24 h and 5 d but
Not at 8w after I/R Injury. Compared to the sham groups,
I/R injury resulted in signiﬁcant apoptotic cell death
(Figures 2(a) and 2(b)) and necrosis (Figure 3, Table 2) in
the IRC groups at 24 h and 5d after I/R injury. TMZ signiﬁ-
cantly attenuated apoptotic cell death and necrosis compared
to the IRCgroups at 24 h and 5 d after I/R injury (Figures 2 and
3, Table 2). At 8w after I/R injury, TUNEL assay and PAS
staining of renal tissues demonstrated almost full recovery of
histopathologic ﬁndings in the IRC and the TMZ-treated
groups, without intergroup diﬀerences (Figures 2 and 3).
3.3. Post I/R Treatment with TMZ Attenuated the Degree of I/
R-Induced Changes in Bcl-2 and Bax Levels at 24 h and 5 d,
but Not at 8w after I/R Injury. Bcl-2 level was signiﬁcantly
decreased, and Bax level was signiﬁcantly increased in the
IRC groups compared to that in the sham groups at 24 h and
5d after I/R injury (Figures 4(a)–4(c)). In line with the antia-
poptotic eﬀect of TMZ, Bcl-2 level was signiﬁcantly higher
and Bax level was signiﬁcantly lower in the TMZ-treated
groups than that in the IRC groups (Figures 4(a)–4(c)). At
8w after renal I/R injury, Bcl-2 and Bax levels were signiﬁ-
cantly greater in the IRC and the TMZ-treated groups than
Table 2: Renal histopathology assessed with PAS staining.
Group Cell degradation Necrosis
Neutrophil
inﬁltration
24 h
Sham Grade 1 Grade 1 Grade 1
IRC 2.6± 0.8∗ 3.6± 0.5∗ 1.3± 0.5
TMZS 1.7± 0.8∗ ,# 1.9± 0.7∗ ,# 1.1± 0.4
5 d
Sham Grade 1 Grade 1 Grade 1
IRC 3.1± 0.9∗ 2.9± 0.9∗ 1.9± 1.2
TMZS 2.1± 0.7 1.3± 0.5# 1.1± 0.4
TMZD 2.1± 0.7 1.6± 0.8# Grade 1
8w
Sham Grade 1 Grade 1 Grade 1
IRC 1.9± 0.4 1.1± 0.4 Grade 1
TMZS 1.4± 0.5 Grade 1 Grade 1
TMZD 1.1± 0.4 Grade 1 Grade 1
PAS = periodic acid-Schiﬀ; TMZ = trimetazidine. Sham = rats not underwent
ischemia-reperfusion; IRC = rats underwent ischemia (45min)-reperfusion
(24 h, 5 d, or 8 w); TMZS = rats treated with TMZ (3mg/kg) upon
reperfusion; TMZD = rats treated with TMZ (3mg/kg) once daily for 5 d
or 8 w starting upon reperfusion. ∗P < 0 05 versus sham, #P < 0 05
versus IRC.
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those in the sham groups, without any intergroup diﬀer-
ences between the IRC and the TMZ-treated groups
(Figures 4(a)–4(c)).
3.4. Post I/R Treatment with TMZ Enhanced the Expression of
HIF-1α and VEGF at 24 h and 5 d, but Not at 8w after I/R
Injury. Renal I/R injury induced increases in HIF-1α levels
(Figures 5(a) and 5(b)) and decreases in VEGF levels
(Figures 5(a) and 5(c)) in the IRC groups compared to that
in the sham groups at 24 h and 5d after I/R injury. Post I/R
treatment with TMZ signiﬁcantly increased both levels of
HIF-1α and VEGF compared to the IRC groups at 24 h and
5d after I/R injury. HIF-1α could not be detected in any
groups at 8w after I/R injury (Figures 5(a) and 5(b)). At
8w after I/R injury, VEGF levels were all signiﬁcantly higher
in the IRC and TMZ-treated groups compared to that in the
sham groups without any intergroup diﬀerences between the
IRC and the TMZ-treated groups (Figures 5(a) and 5(c)).
3.5. Post I/R Treatment with TMZ Did Not Attenuate Renal
Fibrotic Change at 8w after Renal I/R Injury. In Masson’s tri-
chrome staining, renal ﬁbrosis was signiﬁcantly more prom-
inent in the IRC and TMZ-treated groups compared to that
in the sham group at 8w after renal I/R injury, without any
intergroup diﬀerences between the IRC and TMZ-treated
groups (Figures 6(a) and 6(b)).
Post I/R treatment with TMZ reduced the degree of
I/R-induced increases in MMP-2 and MMP-9 levels
(Figures 7(a)–7(c)) and further increased the levels of
TIMP-1 and TIMP-2 (Figures 7(a), 7(d), and 7(e)) at 5 d after
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Figure 4: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on the expressions of Bcl-2 and Bax. Western blot analysis (a) and
densitometric analysis (b, c) of the Western blot for Bcl-2 and Bax at 24 h, 5 d, and 8w after I/R injury, respectively. Bcl-2 level was
signiﬁcantly decreased, and Bax level was signiﬁcantly increased in the IRC groups compared to that in the sham groups at 24 h and 5 d
after I/R injury. Bcl-2 level was signiﬁcantly higher, and Bax level was signiﬁcantly lower in the TMZ-treated groups than that in the IRC
groups. At 8 w after renal I/R injury, Bcl-2 and Bax levels were signiﬁcantly greater in the IRC and the TMZ-treated groups than those in
the sham groups, without any intergroup diﬀerences between the IRC and the TMZ-treated groups. Sham= rats not underwent I/R;
IRC= rats underwent ischemia (45min)-reperfusion (24 h, 5 d, and 8w); TMZS = rats treated with TMZ (3mg/kg) upon reperfusion;
TMZD= rats treated with TMZ (3mg/kg) once daily for 5 d or 8 w starting upon reperfusion. ∗P < 0 05 versus sham, #P < 0 05 versus IRC.
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renal I/R injury compared to the IRC group. At 8w after I/R
injury, MMP levels in the TMZ-treated groups were similar
to those of the IRC groups, which were all signiﬁcantly greater
than those of the sham groups (Figures 7(a)–7(c)). TIMP
levels in the TMZ-treated groups became also comparable to
those of the IRC groups, which were signiﬁcantly greater than
those of the sham groups (Figures 7(a), 7(d), and 7(e)).
4. Discussion
In the current study investigating the impact of post I/R
treatment with TMZ on AKI and its progression to renal
ﬁbrosis against renal I/R injury in a rat model, we observed
signiﬁcant attenuation of renal injury by TMZ at short
(24 h) as well as intermediate (5 d) period after renal I/R
injury. Contrary to its early eﬀects, however, post I/R treat-
ment with TMZ, either given once or daily for 8w, could
not further suppress the progression to renal ﬁbrosis and
expressions of the related signaling pathways compared to
those of the IRC group.
AKI is a major risk factor increasing morbidity and
mortality in hospitalized patients. Notably, renal deteriora-
tion is gradually continued even after complete clinical
recovery from AKI [4, 25]. Despite several favorable exper-
imental results regarding the attenuation of renal I/R injury
[24, 26, 27], the impracticability of providing treatments
from 1 day to 1 month before the renal I/R injury stands
opposed to the clinical translation of these results. Moreover,
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Figure 5: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on the expressions of HIF-1α and VEGF. Western blot analysis (a)
and densitometric analysis (b, c) of the Western blot for HIF-1α and VEGF at 24 h, 5 d, and 8w after I/R injury, respectively. Renal I/R injury
induced increases in HIF-1α levels and decreases in VEGF levels in the IRC groups compared to that in the sham groups at 24 h and 5 d after I/
R injury. Post I/R treatment with TMZ signiﬁcantly increased both levels of HIF-1α and VEGF compared to the IRC groups at 24 h and 5 d
after I/R injury. HIF-1α could not be detected in any groups at 8 w after I/R injury. At 8w after I/R injury, VEGF levels were all signiﬁcantly
higher in the IRC and TMZ-treated groups compared to that in the sham groups without any intergroup diﬀerences between the IRC and the
TMZ-treated groups. Sham= rats not underwent I/R; IRC= rats underwent ischemia (45min)-reperfusion (24 h, 5 d, and 8w); TMZS = rats
treated with TMZ (3mg/kg) upon reperfusion; TMZD= rats treated with TMZ (3mg/kg) once daily for 5 d or 8 w starting upon reperfusion.
∗P < 0 05 versus sham, #P < 0 05 versus IRC.
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although attenuating the early injury is undoubtedly of great
clinical importance, activated signals relevant to the immedi-
ate protective eﬀects could promote injury or impede repair
in the later stages of AKI [28, 29]. In that context, the ﬁnding
that recombinant human erythropoietin delivered after
reperfusion improved renal function and structure in the
acute phase while it contributed to the development of
CKD is worth noting [8].
TMZ is a commonly used antianginal drug with well-
known cardioprotective eﬀect and hemodynamic stability
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Figure 6: Eﬀect of postischemia-reperfusion (I/R) treatment with TMZ on renal tubulointerstitial ﬁbrosis. Representative histology (a) of
renal tubules after Masson’s trichrome staining and quantitative analysis (b) of tubulointerstitial ﬁbrosis. Renal ﬁbrosis was signiﬁcantly
more prominent in the IRC and TMZ-treated groups compared to that in the sham group at 8w after renal I/R injury, without any
intergroup diﬀerences between the IRC and TMZ-treated groups. TMZ= trimetazidine. Sham= rats not underwent I/R; IRC= rats
underwent ischemia (45min)-reperfusion (8w); TMZS = rats treated with TMZ (3mg/kg) upon reperfusion; TMZD= rats treated with
TMZ (3mg/kg) once daily for 8 w starting upon reperfusion. ∗P < 0 05 versus sham.
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Figure 7: Eﬀects of postischemia-reperfusion (I/R) treatment with TMZ on the expressions of MMPs and TIMPs. Western blot analysis (a)
and densitometric analysis (b–e) of the Western blot for MMP-2, -9 and TIMP-1, -2 at 5 d, and 8w after I/R injury, respectively. Post I/R
treatment with TMZ reduced the degree of I/R-induced increases in MMP-2 and MMP-9 levels and further increased the levels of TIMP-
1 and TIMP-2 at 5 d after renal I/R injury compared to the IRC group. At 8w after I/R injury, MMP levels in the TMZ-treated groups
were similar to those of the IRC groups, which were all signiﬁcantly greater than those of the sham groups. TIMP levels in the TMZ-
treated groups became also comparable to those of the IRC groups, which were signiﬁcantly greater than those of the sham groups.
TMZ= trimetazidine. Sham= rats not underwent I/R; IRC= rats underwent ischemia (45min)-reperfusion (5 d or 8w); TMZS = rats
treated with TMZ (3mg/kg) upon reperfusion; TMZD= rats treated with TMZ (3mg/kg) once daily for 5 d or 8 w starting upon
reperfusion. ∗P < 0 05 versus sham, #P < 0 05 versus IRC.
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[30, 31]. Experimentally, TMZ also provided protection
against renal I/R injury through its antioxidative, anti-
inﬂammatory, and antiapoptotic eﬀects [15, 32]. Of particu-
lar interest, TMZ inhibited delayed renal ﬁbrosis through
upregulation of HIF-1α in pigs after I/R injury [6]. Based
on the theoretical advantages of TMZ and the clinical practi-
cability of applying treatment after the onset of AKI, we
investigated the eﬀects of a single and repeated post I/R treat-
ment of TMZ on AKI and its progression to renal ﬁbrosis
after renal I/R injury, while no comprehensive evidence exists
in that regard.
In the current study, post I/R treatment with TMZ
conferred renoprotective eﬀects at 24 h and 5d after I/R
injury. Post I/R treatment with TMZ signiﬁcantly mitigated
apoptotic cell death and necrosis that were associated with
inhibition of apoptotic pathways, enhanced expression of
HIF-1α, and attenuated reduction in the VEGF level. TMZ
treatment also resulted in upregulation of TIMPs and down-
regulation of MMPs. These results were consistent with those
of previous studies that demonstrated the organ-protective
eﬀects of TMZ administered after ischemic insult on the
heart, retina, and testis [33–35], mainly ascribed to its antiox-
idative property.
Contrary to the protective eﬀects observed in the short-
and intermediate-term, however, TMZ could not prevent
renal ﬁbrosis at 8w after renal I/R injury in the present study.
At 8w, all protein expressions including VEGF, MMPs, and
TIMPs as well as Bcl-2 and Bax were enhanced compared
to those in the sham group. TMZ-induced early modulation
of these signal protein expressions disappeared, resulting in
comparable expression levels of all measured signal proteins
among the IRC and TMZ-treated groups. These results are
discordant with the results of previous reports showing that
TMZ could reduce ﬁbrosis development after I/R injury in
pigs [6] and attenuate interstitial ﬁbrosis in cyclosporine
A-induced nephrotoxicity in rats [36].
A complex interplay of multiple mechanisms contrib-
utes to I/R-induced organ damage. In the hypoxic kidney,
HIF-1α is expressed predominantly in tubular epithelial
cells and works as a master regulator of hypoxic stress
[7, 37]. In the current study, renal I/R injury elicited sig-
niﬁcant increase in the HIF-1α level, which was further
increased by post I/R treatment with TMZ both at 24 h
and 5d after renal I/R injury. Despite the increased HIF-
1α level, VEGF activities were signiﬁcantly lower in the
IRC group compared to that in the sham group, while
its activities were signiﬁcantly increased with TMZ treat-
ment at 24 h and 5d after renal I/R injury. In line with
this, VEGF expression in the proximal tubules was
reported to be lost early after AKI without treatment
[38]. VEGF, regulated by HIF-1α, is involved in the regu-
lation of the expression of many genes that help to reduce
renal injury after I/R injury [4]. Thus, increased expression
of HIF-1α accompanied by enhanced expression of VEGF
with TMZ might contribute to the reduction of early renal
injury after I/R in the present study. Of note, at 8w after
I/R injury, VEGF expressions were signiﬁcantly greater in
both the IRC and TMZ-treated groups than those of the
sham groups, while HIF-1α could no more be detected
in all groups. These ﬁndings indicate a delayed increase
in VEGF independent of HIF-1α. Dysangiogenic VEGF,
produced by intercellular proteolysis independent of HIF-
1α, has been shown to elicit loss of endothelial integrity
[39] and loss of nursing function of pericytes that stabilize
capillaries [40]. Therefore, activated protective signals
needed for the early phase but not removed in a timely
manner may contribute to the continued production of
proﬁbrotic factors and the progression of renal ﬁbrosis [8].
In the present study, TMZ attenuated expressions of
MMPs and enhanced expressions of TIMPs at 5 d after
I/R injury. Early after renal I/R injury, the inﬂux of
inﬂammatory mediators together with the degradation of
necrotic cells induce upregulation of degradative enzymes
in the renal interstitium [41–43]. Among the degradative
enzymes, MMP-2 is particularly important. It has a high
activity against collagen IV or basement membrane [44]
and causes vascular endothelial damage [45]. Indeed, inhi-
bition of MMPs has been shown to reduce I/R-induced
AKI [41]. In that context, attenuated activation of MMPs
with TMZ might have conveyed beneﬁcial inﬂuence in
mitigating the renal damage at 5 d after renal I/R injury
in this study. After renal I/R injury, TIMPs, inhibitors of
MMPs, are activated as well to counteract extracellular
matrix degradation by MMPs. Therefore, the augmented
activation of TIMPs at 5 d after renal I/R injury in the cur-
rent study might have added favorable eﬀects by suppress-
ing the activities of MMPs in the TMZ-treated groups. On
the other hand, expression levels of MMPs and TIMPs all
remained greater in the IRC and the TMZ-treated groups
than those of the sham groups at 8w after renal I/R
injury. Similar ﬁndings were observed in the previous
study that assessed changes in the levels of MMPs and
TIMPs for 24w after renal I/R injury [46]. In that study,
after an initial phase of increased extracellular matrix
turnover following I/R injury, the balance subsequently
turned towards the development of ﬁbrosis, which was
suggested to be the result of decreased extracellular matrix
degradation by continuous activation of TIMPs [46]. Thus,
our ﬁndings indicate that the oﬀset of the balance between
MMPs and TIMPs resulting in persistent enhancement of
both molecules may have acted towards the development
of interstitial ﬁbrosis.
Contrary to our expectations, although a single dose was
suﬃcient to exert early- and intermediate-term renoprotec-
tion, daily TMZ treatment did not exert additional eﬀect over
a single dose in the current study. Yet, considering that the
elimination half-life of TMZ is approximately 6 h [47],
employing an administration protocol of TMZ (2 to 3
times/day) yielding a steady state of the drug may have
resulted in a diﬀerent long-term outcome, which is a clear
limitation of this study.
5. Conclusions
In conclusion, post I/R treatment with TMZ might allow
ischemic kidneys to regain renal function and structure
more rapidly compared to nontreated kidneys but not
enough to resolute renal ﬁbrosis in long-term aspect.
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Despite that, the early and intermediate renoprotective
eﬀects of TMZ treatment after I/R injury as aﬃrmed by
upregulation of HIF-1α, VEGF, and the inhibition of apo-
ptotic pathways related to Bax deserve a clinical attention
since the degree of recovery after AKI would signiﬁcantly
be associated with chronic renal function [48].
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